Initiation of Biosceptre’s Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06v Initiation of Biosceptre’s Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06vBiosceptre2019-12-12T16:01:47+11:00August 21st, 2018|News|Read More
Biosceptre Paper published by Oncogene Biosceptre Paper published by OncogeneBiosceptre2019-12-12T16:02:28+11:00August 12th, 2018|News|Read More
Biosceptre attending ASCO 2018 Biosceptre attending ASCO 2018Biosceptre2019-12-09T13:41:47+11:00May 14th, 2018|News|Read More
Biosceptre presenting a poster at AACR 2018 Biosceptre presenting a poster at AACR 2018Biosceptre2019-12-09T13:49:41+11:00March 6th, 2018|News|Read More
Biosceptre’s Phase 1 Clinical Trial for anti-cancer vaccine BIL06v approved by Ethics CommitteeBiosceptre2019-12-12T15:58:08+11:00March 1st, 2018|News|Read More
Biosceptre welcomes Tuspark S & T into its Series A fund raising roundBiosceptre2019-12-12T15:57:02+11:00December 14th, 2017|News|Read More
Biosceptre Joins European Cooperation in Science & Technology COST Group BMBS 1406 – with focus on Ion Channels and Immune ResponseBiosceptre2019-12-12T15:47:28+11:00June 13th, 2017|News|Read More
Professor Paul de Souza joins Biosceptre executive team as Chief Medical OfficerBiosceptre2019-12-12T15:51:30+11:00April 28th, 2017|News|Read More
Biosceptre’s Phase 1 Clinical Trial for anti-cancer antibody BIL03s approved by Ethics CommitteeBiosceptre2017-03-17T00:42:54+11:00March 17th, 2017|News|Read More
